ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Immunosuppressants >Lemborexant

Lemborexant

Lemborexant Structure
CAS No.
1369764-02-2
Chemical Name:
Lemborexant
Synonyms
E 2006;CS-2189;Dayvigo.;labradon;Lemborexant;Lemborexant API;lemborexant,E2006;E-2006 Lemborexant;Lemborexant USP/EP/BP;Lemborexant Impurity 1
CBNumber:
CB72744022
Molecular Formula:
C22H20F2N4O2
Molecular Weight:
410.42
MOL File:
1369764-02-2.mol
MSDS File:
SDS
Modify Date:
2024/3/29 9:40:28

Lemborexant Properties

Melting point 173 - 175°C
Boiling point 596.1±50.0 °C(Predicted)
Density 1.347±0.06 g/cm3(Predicted)
storage temp. -20°C, Inert atmosphere
solubility DMSO (Slightly), Methanol (Slightly)
pka 12.30±0.40(Predicted)
form Solid
color White to Off-White

SAFETY

Risk and Safety Statements

DEA Controlled Substances CSCN: 2245
CAS SCH: IV
NARC: N

Lemborexant Chemical Properties,Uses,Production

Description

Lemborexant is a newer orexin receptor antagonist which is submitted to US FDA for review as new drug application for the treatment of insomnia after completing two key Phase 3 studies of lemborexant – SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303).

Chemical Properties

Lemborexant is a white to off-white powder that is practically insoluble in water.

Uses

Lemborexant is a novel orexin receptor antagonist and is used in the treatment of insomnia, characterised by difficulties with sleep onset or sleep maintenance. Orexins are neuropeptides involved in regulating sleep and arousal by promoting wakefulness. Lemborexant blocks the binding of orexins A and B to their receptors 1 and 2 thereby reducing wakefulness and promoting sleep. Suvorexant is the other orexin receptor antagonist marketed in Australia for insomnia.

Pharmacokinetics

Effect of food High-fat & high-calorie meal delay Tmax & reduce Cmax
Tmax 1 to 3 hours
Half-life 17 hours (5 mg) and 19 hours (10 mg)
Metabolism primarily metabolized by CYP3A4
Excretion Urine (29%); feces (57%)

Drug interactions

Lemborexant is metabolized by CYP3A4 and is susceptible to interactions with medications such as amiodarone, amlodipine, carbamazepine, clarithromycin, diltiazem, fluoxetine and phenytoin. Lemborexant may affect other medications metabolised by CYP2B6, such as bupropion and methadone. Alcohol should be avoided: a single dose of alcohol can increase lemborexant concentrations up to 70%.

Mode of action

The mechanism of action of lemborexant in the treatment of insomnia is Blocks the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R, presumed to suppress wake drive.

References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
https://www.smchealth.org/sites/main/files/file-attachments/dayvigo_for_publish.pdf?1592332002
https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/Lemborexant%20(Dayvigo)%20(CP.PMN.233)%20(PDF).pdf

Lemborexant Preparation Products And Raw materials

Raw materials

Preparation Products

Lemborexant Suppliers

Global( 122)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Bulat Pharmaceutical Pvt Ltd +91-8448085659 +91-8448085660 Haryana, India 123 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Hebei Mojin Biotechnology Co., Ltd +86 13288715578 +8613288715578 China 12460 58 Inquiry
Henan Bao Enluo International TradeCo.,LTD +86-17331933971 +86-17331933971 China 2503 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29826 58 Inquiry
ANHUI WITOP BIOTECH CO., LTD +8615255079626 China 23556 58 Inquiry
Dideu Industries Group Limited +86-29-89586680 +86-15129568250 China 26165 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15395 58 Inquiry

Related articles

  • The synthesis method of Lemborexant
  • Lemborexant is an orally administered dual orexin receptor (OXR) antagonist developed by Eisai for the treatment of adults wit....
  • Jan 8,2024

1369764-02-2(Lemborexant)Related Search:

(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide E 2006 Lemborexant lemborexant,E2006 (1R,2S)-2-[(2,4-DIMETHYLPYRIMIDIN-5-YL)OXYMETHYL]-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL)CYCLOPROPANE-1-CARBOXAMIDE lemborexant / E-2006, CID 56944144 E-2006 Lemborexant 2-((1S,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)cyclopropyl)-N-(5-fluoropyridin-2-yl)acetamide CS-2189 Dayvigo. E-2006; E 2006; E2006; LEMBOREXANT; DAYVIGO. Cyclopropanecarboxamide, 2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S)- Lemborexant USP/EP/BP Lemborexant Impurity 1 Lemborexant API labradon 1369764-02-2 API 1369764-02-2